Lawrence P. Guiheen - 21 May 2025 Form 4 Insider Report for ADMA BIOLOGICS, INC. (ADMA)

Role
Director
Signature
/s/ Lawrence P. Guiheen, by Adam S. Grossman as Attorney-in-fact
Issuer symbol
ADMA
Transactions as of
21 May 2025
Net transactions value
-$128,996
Form type
4
Filing time
23 May 2025, 21:00:30 UTC
Previous filing
21 Feb 2025
Next filing
11 Jun 2025

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Guiheen Lawrence P. Director C/O ADMA BIOLOGICS, INC., 465 STATE ROUTE 17, RAMSEY /s/ Lawrence P. Guiheen, by Adam S. Grossman as Attorney-in-fact 23 May 2025 0001554353

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ADMA Common Stock Options Exercise $46,363 +7,779 +6.8% $5.96 122,609 21 May 2025 Direct
transaction ADMA Common Stock Sale $158,069 -7,779 -6.3% $20.32 114,830 21 May 2025 Direct F1
transaction ADMA Common Stock Options Exercise $7,277 +1,221 +1.1% $5.96 116,051 22 May 2025 Direct
transaction ADMA Common Stock Sale $24,567 -1,221 -1.1% $20.12 114,830 22 May 2025 Direct F2
holding ADMA Common Stock 50,990 21 May 2025 See footnote F3, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ADMA Stock Option (right to buy) Options Exercise $0 -7,779 -86% $0.000000 1,221 21 May 2025 Common Stock 7,779 $5.96 Direct F5, F6
transaction ADMA Stock Option (right to buy) Options Exercise $0 -1,221 -100% $0.000000 0 22 May 2025 Common Stock 1,221 $5.96 Direct F5, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.20 to $20.73. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
F2 Includes, as of the transaction date, (i) 10,889 restricted stock units granted on February 19, 2025, which vest in two equal installments, on the six- and 12-month anniversaries of the grant date, becoming fully vested on the one-year anniversary of the grant date, subject to the Reporting Person's continued service as of such vesting date; and (ii) 103,941 shares of common stock owned by the Reporting Person. The number of common shares reported includes a de minimis reduction by 10 shares from the amount previously reported due to a broker adjustment.
F3 Includes 50,990 shares of common stock held in the Lawrence P Guiheen Irrevocable Trust 1 (the "Guiheen Irrevocable Trust"), of which 49,990 shares were inadvertently reported in prior reports as directly owned.
F4 These shares are owned by the Guiheen Irrevocable Trust.
F5 The Reporting Person is exercising this option due, in part, to its near-term expiration date.
F6 These options were granted on January 28, 2016 and vested in twenty-four equal monthly installments, becoming fully vested on January 28, 2018.